Fengqi Liu

Fengqi Liu

Auto-generated profile, based on publicly available information

Fengqi Liu

Department of Neurology The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital Nanjing China

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2024 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
TLTao-Ran Li
Tao-Ran Li
BLBai-Le Li
Bai-Le Li
XXXin-Ran Xu
Xin-Ran Xu
JZJin Zhong
Jin Zhong
TWTai-Shan Wang
Tai-Shan Wang
TIThe Alzheimer’s Disease Neuroimaging Initiative
The Alzheimer’s Disease Neuroimaging Initiative
Background: The relationship between white matter hyperintensities (WMH) and the core features of Alzheimer’s disease (AD) remains controversial. Further, due to the prevalence of co-pathologies, the precise role of WMH in cognition and neurodegeneration also remains uncertain.Methods: Herein, we analyzed 1803 participants with available WMH volume data, extracted from the ADNI database, including 756 cognitively normal controls, 783 patients with mild cognitive impairment (MCI), and 264 patients with dementia. Participants were grouped according to cerebrospinal fluid (CSF) pathology (A/T profile) severity. Linear regression analysis was applied to evaluate the factors associated with WMH volume. Modeled by linear mixed-effects, the increase rates (Δ) of the WMH volume, cognition, and typical neurodegenerative markers were assessed. The predictive effectiveness of WMH volume was subsequently tested using Cox regression analysis, and the relationship between WMH/ΔWMH and other indicators such as cognition was explored through linear regression analyses. Furthermore, we explored the interrelationship among amyloid-β deposition, cognition, and WMH using mediation analysis.Results: Higher WMH volume was associated with older age, lower CSF amyloid-β levels, hypertension, and smoking history (all p ≤ 0.001), as well as cognitive status (MCI, p < 0.001; dementia, p = 0.008), but not with CSF tau levels. These results were further verified in any clinical stage, except hypertension and smoking history in the dementia stage. Although WMH could not predict dementia conversion, its increased levels at baseline were associated with a worse cognitive performance and a more rapid memory decline. Longitudinal analyses showed that baseline dementia and positive amyloid-β status were associated with a greater accrual of WMH volume, and a higher ΔWMH was also correlated with a faster cognitive decline. In contrast, except entorhinal cortex thickness, the WMH volume was not found to be associated with any other neurodegenerative markers. To a lesser extent, WMH mediates the relationship between amyloid-β and cognition.Conclusion: WMH are non-specific lesions that are associated with amyloid-β deposition, cognitive status, and a variety of vascular risk factors. Despite evidence indicating only a weak relationship with neurodegeneration, early intervention to reduce WMH lesions remains a high priority for preserving cognitive function in the elderly.

19 February 2008 in Marine Biotechnology
Verified
Journal Article
Closed access
PDF file
QZQian Zhou
Qian Zhou
CWChanggong Wu
Changgong Wu
Bo DongBo Dong
Bo Dong
FLFengqi Liu
Fengqi Liu
JXJianhai Xiang
Jianhai Xiang

20 June 2024 in Chinese Medical Journal
Verified
Journal Article
Open access
SZShuzhe Zhou
Shuzhe Zhou
PLPei Li
Pei Li
XLXiaozhen Lv
Xiaozhen Lv
XLXuefeng Lai
Xuefeng Lai
ZLZuoxiang Liu
Zuoxiang Liu
FSFeng Sun
Feng Sun
Background: The optimal antidepressant dosages remain controversial. This study aimed to analyze the efficacy of antidepressants and characterize their dose–response relationships in the treatments of major depressive disorders (MDD). Methods: We searched multiple databases, including the Embase, Cochrane Central Register of Controlled Trials, PubMed, and Web of Science, for the studies that were conducted between January 8, 2016, and April 30, 2023. The studies are double-blinded, randomized controlled trials (RCTs) involving the adults (≥18 years) with MDD. The primary outcomes were efficacy of antidepressant and the dose–response relationships. A frequentist network meta-analysis was conducted, treating participants with various dosages of the same antidepressant as a single therapy. We also implemented the model-based meta-analysis (MBMA) using a Bayesian method to explore the dose–response relationships. Results: The network meta-analysis comprised 135,180 participants from 602 studies. All the antidepressants were more effective than the placebo; toludesvenlafaxine had the highest odds ratio (OR) of 4.52 (95% confidence interval [CI]: 2.65–7.72), and reboxetine had the lowest OR of 1.34 (95%CI: 1.14–1.57). Moreover, amitriptyline, clomipramine, and reboxetine showed a linear increase in effect size from low to high doses. The effect size of toludesvenlafaxine increased significantly up to 80 mg/day and subsequently maintained the maximal dose up to 160 mg/day while the predictive curves of nefazodone were fairly flat in different dosages. Conclusions: Although most antidepressants were more efficacious than placebo in treating MDD, no consistent dose–response relationship between any antidepressants was observed. For most antidepressants, the maximum efficacy was achieved at lower or middle prescribed doses, rather than at the upper limit. Registration: No. CRD42023427480; https://www.crd.york.ac.uk/prospero/display_record.php?

1 July 1993 in Applied Superconductivity
Verified
Journal Article
Closed access
JZJincang Zhang
Jincang Zhang
FLFengqi Liu
Fengqi Liu
JLJunzheng Liu
Junzheng Liu
SCShixun Cao
Shixun Cao
HGHansheng Guo
Hansheng Guo

18 September 2024 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
TLTao‐Ran Li
Tao‐Ran Li
BLBai‐Le Li
Bai‐Le Li
JZJin Zhong
Jin Zhong
XXXin‐Ran Xu
Xin‐Ran Xu
TWTai‐Shan Wang
Tai‐Shan Wang
FIFor The Alzheimer'S Disease Neuroimaging Initiative
For The Alzheimer'S Disease Neuroimaging Initiative
Aims: The early stages of Alzheimer's disease (AD) are no longer insurmountable. Therefore, identifying at‐risk individuals is of great importance for precise treatment. We developed a model to predict cognitive deterioration in patients with mild cognitive impairment (MCI).Methods: Based on the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, we constructed models in a derivation cohort of 761 participants with MCI (138 of whom developed dementia at the 36th month) and verified them in a validation cohort of 353 cognitively normal controls (54 developed MCI and 19 developed dementia at the 36th month). In addition, 1303 participants with available AD cerebrospinal fluid core biomarkers were selected to clarify the ability of the model to predict AD core features. We assessed 32 parameters as candidate predictors, including clinical information, blood biomarkers, and structural imaging features, and used multivariable logistic regression analysis to develop our prediction model.Results: Six independent variables of MCI deterioration were identified: apolipoprotein E ε4 allele status, lower Mini‐Mental State Examination scores, higher levels of plasma pTau181, smaller volumes of the left hippocampus and right amygdala, and a thinner right inferior temporal cortex. We established an easy‐to‐use risk heat map and risk score based on these risk factors. The area under the curve (AUC) for both internal and external validations was close to 0.850. Furthermore, the AUC was above 0.800 in identifying participants with high brain amyloid‐β loads. Calibration plots demonstrated good agreement between the predicted probability and actual observations in the internal and external validations.Conclusion: We developed and validated an accurate prediction model for dementia conversion in patients with MCI. Simultaneously, the model predicts AD‐specific pathological changes. We hope that this model will contribute to more precise clinical treatment and better healthcare resource allocation.

27 February 2017 in Journal of Investigative Surgery
Verified
Journal Article
Closed access
DLDan Li
Dan Li
WLWei Liu
Wei Liu
DMDan Ma
Dan Ma
FYFengxiang Yun
Fengxiang Yun
SLShu Li
Shu Li
FLFengqi Liu
Fengqi Liu
Background: The pilot study is designed to investigate the effect of continuous thoracic sympathetic block (TSB) on cardiac function, reconstruction, and hemodynamic parameters in patients with heart failure resulting from valvular heart disease. Method: The cardiac function parameters, including left ventricle ejection fraction (LVEF), left ventricle end-diastole diameter (LVEDD), fractional shortening (FS), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP), were measured in 19 patients before and after TSB treatment. The patients were also classified on the basis of NYHA classification system. Results: 4 weeks of TSB administration improved cardiac function in 18 of 19 patients (94.74%). The patients' LVEF, LVEDD, and NT-proBNP were all improved significantly after treatment. Conclusions: The favorable clinical outcome of TSB administration suggests an alternative treatment for the patients with heart failure caused by valvular dysfunctions.